| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Maze Therapeutics, Inc. | SVP, Finance | Common Stock | 12,965 | $604,587 | $46.63 | 02 Feb 2026 | Direct |
| Maze Therapeutics, Inc. | SVP, Finance | Stock Option (Right to Buy) | 41,333 | 02 Feb 2026 | Direct | ||
| Maze Therapeutics, Inc. | SVP, Finance | Restricted Stock Units | 22,000 | 22 Sep 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| MAZE | Maze Therapeutics, Inc. | 02 Feb 2026 | 7 | -$178,119 | 4 | SVP, Finance | 04 Feb 2026, 16:23 |
| MAZE | Maze Therapeutics, Inc. | 22 Jan 2026 | 5 | -$175,512 | 4 | SVP, Finance | 26 Jan 2026, 16:10 |
| MAZE | Maze Therapeutics, Inc. | 02 Jan 2026 | 6 | -$143,654 | 4 | SVP, Finance | 06 Jan 2026, 16:30 |
| MAZE | Maze Therapeutics, Inc. | 29 Dec 2025 | 11 | -$449,873 | 4 | SVP, Finance | 31 Dec 2025, 16:20 |
| MAZE | Maze Therapeutics, Inc. | 22 Sep 2025 | 1 | $0 | 4 | SVP, Finance | 24 Sep 2025, 16:23 |
| MAZE | Maze Therapeutics, Inc. | 30 Jan 2025 | 0 | $0 | 3 | SVP, Finance | 30 Jan 2025, 16:21 |